Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5-11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

• Main Authors: Elio Novembre (Author), Mariangela Tosca (Author), Carlo Caffarelli (Author), Mauro Calvani (Author), Fabio Cardinale (Author), Riccardo Castagnoli (Author), Elena Chiappini (Author), Claudio Cravidi (Author), Michele Miraglia Del Giudice (Author), Marzia Duse (Author), Amelia Licari (Author), Sara Manti (Author), Alberto Martelli (Author), Giampaolo Ricci (Author), Giuseppe Pingitore (Author), Gian Luigi Marseglia (Author)
• Format: Book
• Published: BMC, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a...